universities are leveraging the financial resources of drug companies with the tissue and research resources of academia." Many clinical cancer trials today have a tissue collection element to better understand the relationship between treatment and tumor biology, explore pharmacogenetics, or develop lab assays to help targeted therapy. 12 There tends to be an overlap, redundancy and waste, because tissue is often collected for only one purpose and the information gathered is proprietary.
Biobanking has been given a green light, but it is forging ahead with many unsettled ethical and legal issues associated with the collection, maintenance, control and use of tissue and the information derived from tissue.13 This essay will examine the advantages and shortcomings of the current state of legal rights describing human tissue, and then offer a new way that better recognizes the distinction between, and interdependence of, tissue and tissue information, while balancing important interests and maintaining incentives to realize the potential of personalized medicine. The new way begins by recognizing the unique attributes of human tissue, including how it is related to information derived from it and its importance of annotated Biorepositories and the maintenance of tissue banks for the future of personalized medicine, bemoaned that participation in clinical trials is not the norm today, and reminded readers that it is only through clinical trials that personalized medicine can deliver its promise).
See, e.g., Selina McKee, Pfizer Hooks Up with Uni of California in Novel Research
13. See Park, supra note 4 (explaining that privacy is the biggest challenge facing biobanks and that the accessibility of DNA by the government makes people uncomfortable). Many scholars have concluded that the laws regulating excised tissue ownership remain poorly defined and some have pleaded for new approaches to address the issues presented by large scale biobanking. See Stephanie M. In an article about the electronic medical record, Mark Hall asks whether it matters that the law does not give a clear, complete and consistent answer to the question of who owns medical information. Hall, supra note 4, at 642. He notes that the Coase Theorem says it doesn't matter as long as transaction costs are not so expensive as to prohibit reallocation through contracting. Id. Hall, however, concludes that property rights must be clear so that parties know their default positions, and that such clarity is absent with medical information property rights. Id. at 637, 645. similarity to clinical health information. 14 The argument continues with the help of Henry Smith's work, and examines and describes biobanks as a semicommons.1 5 This essay concludes by outlining a legal infrastructure that would make information derived from tissue in biobanks more accessible to the research community and better able to protect the interests of people who have donated tissue. 16 In Part II, this essay will examine the current legal landscape governing human tissue, beginning with Moore v. Regents of the University of California. 17 Moore opened the way for subsequent cases, like Washington University v. Catalona18 and Greenberg v. Miami Children's Hospital Research Institute, Inc.,i9 which characterize patient tissue, almost by definition, as gifts to the research institution. The practical approach taken by Moore and its progeny, which all involved research universities, as well as the current federal Common Rule governing research, have allowed tissue banking and biobanking to go forward because the legal landscape has given research universities property interests in tissue with little threat of tissue donors successfully claiming property or other legal rights in their tissue, or any legal claim to profits derived from research on the tissue. 20 Part III will explore a new legal description of excised human tissue derived from understanding its unique attribute, that places it in a space between private property, public property, and intellectual property. Although Moore recognized the distinction between tissue and information supplied by the tissue, it failed to explore the nexus between the two. Several attributes of excised tissue make it unique. First, human tissue that is not going to be used for clinical purposes, such as diagnosis, transplantation or transfusion, has no commercial value unless it is transformed into a commodity. 21 Tissue increases in value as it is linked to treatment and outcomes information, because the molecular characteristics of the tissues gain meaning. 22 Only with this linked information can one determine, for example, whether a particular mutation responds to a particular targeted therapeutic. 23 Secondly, one piece of human tissue generally means little but gains value as it is linked with many others. 24 Thirdly, although human tissue is unique to each individual, research on one person's tissue may benefit others. 25 We have a shared interest in tissue research because it may benefit us, our families, and our communities. Lastly, whereas the tissue itself is rival (others cannot use it if you are), the information from the tissue is non-rival. 26 Understanding these attributes of excised human tissue recognizes the similarities between information derived from tissue and other clinical medical information. It means both types of information may be best defined as a common shared resource to be used for public benefit. Part IV will describe biobanks as liberal semicommons, and how this characterization will change the look of biobanks. New biobanks, while still holding many sticks in the property bundle, will not hold all of the sticks, because tissue and tissue information will be part of a semicommons. This approach draws on previous property work describing semicommons and liberal commons. 27 Such an approach better recognizes the altruistic intent of tissue donors and the inherent public health aspects of tissue research, while not tearing apart the current regime. The proposed approach recognizes lessons taught by previous biobanks, promotes long term benefits, such as encouraging patient participation in clinical trials, leverages rare disease tissue, and generally promotes the sustainability of biobanking.
2 8 Part V identifies areas of concern and identifies some of the implications of treating biobanks as liberal semicommons.
See
McDermott et al., supra note 1, at 343 (stipulating that due to the prevalence of disease mutations, an approach to research using linked information-utilizing tissue samples from a large sample of patients-is necessary to develop targeted drugs).
24. See supra note 22 and accompanying text.
25.
See, e.g., Moore v. Regents of Univ. of Cal., 793 P.2d 479, 481 n.2 (Cal. 1990) (explaining that tissue from one person can lead to the development of therapies that will benefit others by manufacturing the benefits of the tissue using techniques of recombinant DNA).
26. See infra notes 260-66 and accompanying text. 
II. CURRENT LAW GOVERNING EXCISED TISSUE

A. Moore v. University of California Introduces the Issues
Moore v. University of California is a well-known and extensively analyzed case, 29 which comprehensively addressed the legal rights of a patient who did not know that his tissue was being used for commercial development (and for research).
3 0 Scholars recognized early on that the case was important because it addressed important evolving issues. 3 ' Moore is one reason why informed consent forms for clinical trials routinely include statements that the research subjects have no interests in any commercial benefit derived from research on their tissue. 32 It also established the rationale behind why many research hospitals use broad release forms for research use of tissue removed for clinical purposes. 33 The following, 32. See, e.g., Korobkin, supra note 29, at 3. Regardless of whether a written and signed informed consent has aspects of a contract, the effect of the decision in Moore has been that in the clinical setting patients have no right to proceeds from their tissue unless separately negotiated. Id.
33. See, e.g., Hartman, supra note 31, at 463 (noting that the Moore court imposed a duty on physicians of full disclosure as to personal interests to patients as part of the informed consent process). An example of a hospital "consent" is:
By signing my name below, I confirm the following: I have read (or had read to me) this entire consent document. The decision saw a conflict between medical progress and human privacy and dignity.
50
The Court of Appeals understood that times were changing; tissue traditionally had little financial value but now was taking on "astonishing aspects of value," a fact that "requires examination of our understanding of the legal rights and relationships in the human body and the human cell. Moore's cell-line had already been commercialized by defendants, the only question it would consider was which party should share in the profits. Id. However, because of the specter of slavery, the court approached the issue with caution, emphasizing that it was not determining whether use of tissue "ought to be 'gift based' or subject to a 'free market."' Id.
54. Id. at 507.
made it property. 55 Moore maintained his tissue had value, perhaps minimal value, but enough, nonetheless, so that it could be converted.
56
The Court of Appeals responded to the defendants' argument, that Moore's tissue had value only because of the work and intellectual capital invested, by focusing on the difference between the tissue and information or ideas derived from the tissue. 57 First, it noted that the plaintiffs complaint alleged conversion of the cells and not conversion of the "ideas gained from study of the cells." 58 The court then argued that, without the cells, the information would never have been uncovered. 59 Therefore, the cells were of at least some value and there was a nexus between the tissue and information derived from the tissue. 60 The court cited a number of property and privacy cases, as well as health and safety codes to make the point that there was some value in the unimproved removed tissue, so that "it cannot be said that a person has no property right in materials which were once part of his body."
61
In reaching its decision, The case involved a dispute between a powerful research institution and a well-known urologist/researcher who wanted to have his patients' banked tissue transferred from the biorepository at Washington University (WU) to his new place of employment, Northwestern University. Id. at 670, 672. Catalona sent a letter and release form to between 50,000 to 60,000 people asking that their tissue and blood samples be released to "Dr. Catalona at Northwestern University upon his request." Id. at 672. The release form also stated, "I have entrusted these samples to Dr. Catalona to be used only at his discretion and with his express consent for research projects." Id. About 6,000 people signed and returned the forms. Id. The appellate court held that the tissue was a valid inter vivos gift from patients to WU so that patients/subjects retained no sufficient ownership interest to direct or authorize transfer of tissue to another institution. Id. at 674. As Moore prevented an anticommons of each individual tissue donor increasing transaction costs to insurmountable levels, Catalona prevented a feudal system of researcher fiefdoms. Greenberg, decided before Catalona, is, as the federal district court described the case, "a tale of a successful research collaboration gone sour."" 8 Greenberg's facts are solidly and solely in a research setting," 9 but the opinion ignored its own description of the research being "collaborative." Judge Moreno failed to recognize any of the collaborating plaintiffs' contributions, dismissing five of the six causes of action, including conversion, lack of informed consent, and misappropriation of trade secrets, and only allowed the plaintiffs claim for unjust enrichment to 116. Park, supra note 4 (describing that biobanks have the potential to revolutionize medical treatment options because they contain a variety of tissue samples). The court could have explicitly used a contract analysis, and in fact, the Catalona court analyzed the case facts like a contract, looking at the language of the informed consent forms and placing significant value on the language in the genetic research information brochure. Catalona, 490 F.3d at 674-76. The court continued, adopting an unstated adverse possession analysis, by looking at Dr. Catalona's actions to determine whether patients retained any ownership interest, finding it "difficult to reconcile the use, consumption, and destruction of biological materials by Dr. Catalona and the events that occurred during the research process with the assertion the [ 119. Id. at 1066-68. The facts in Greenberg can be summarized as follows: Dan and Debbie Greenberg gave birth to two children diagnosed with Canavan disease, a rare, fatal, inheritable, and incurable genetic disease. Id. at 1066. They sought out Dr. Matalon to help research and find better ways to diagnose and treat the disease. Id. The family worked with Dr. Matalon to collect tissue and create a Canavan registry, which included information about the Canavan families. Id. Matalon successfully isolated the Canavan gene, and along with Miami Children's Hospital (MCH), patented the gene. Id. at 1067. MCH proceeded to exercise its patent rights and restricted the ability of various clinical labs to test for the gene, which impaired carrier and prenatal testing. Id. This was contrary to the intentions of the Canavan families who wanted their tissue and the registry information to be for the public good. Id.
continue.1 20 The parties eventually reached a confidential out of court settlement.121
In Greenberg, the tissue donor's property rights were found to "evaporate once the sample is voluntarily given to a third party," and, foreshadowing Catalona, the decision observed that the tissues "were donations to research without any contemporaneous expectations of return. 
C. The Proposal to Ease the Common Rule's Consent Requirements for Tissue Research
The Common Rule, the federal law governing human subjects research, is applicable to all research institutions that accept federal funding. 126 Current interpretation of the Common Rule is that research on tissue, without personally 120. Id. at 1070-77. Moreno reasoned that an informed consent claim was misplaced because, unlike Moore, the Greenberg facts were not in a clinical care setting and Florida law did not include a duty for researchers to disclose economic interests and other potential conflicts of interests because such a duty would be "unworkable and chill medical research" as well as "give rise to a type of dead-hand control that research subjects could hold because they would be able to dictate how medical research progresses." Id. 124. Admittedly, it may be, as Russell Korobkin argues, that Moore established no more than a default rule for no compensation for patients and subjects who supply their human tissue, but it is a powerful rule that requires significant effort, cost and organization to circumvent. See Korobkin, supra note 29, at 3, 5-6. One example of a group successfully negotiating around the Moore baseline is a group, PXE International, providing researchers with tissue samples from patients with pseudoxanthoma elasticum in exchange for shared patent rights to the disease-causing gene. of existing data, documents, records, pathological specimens, or diagnostic specimens, if these sources are publicly available or the information is recorded by the investigator in such a manner that the subjects cannot be identified directly or through identifiers linked to the subjects").
See § 46.116(d)
An IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth in this section, or waive the requirements to obtain informed consent provided the IRB finds and documents that: (1) The research involves no more than minimal risk to the subjects; (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects; (3) The research could not practicably be carried out without the waiver or alteration; and (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation. 138. 45 C.F.R. § § 164.502(d)(2), .514(a) (2010). HIPAA's restrictions are also generally inapplicable to health information that is de-identified. See 45 C.F.R. § 164.514(a) (2010) ("Health information that does not identify an individual and with respect to which there is no reasonable basis to believe that the information can be used to identify an individual is not individually identifiable health information."). The Privacy Rule recognizes that the research arena justifies disclosure without patient/subject authorization in some instances. Id. § 164.514(c) (stating that limited health information may be disclosed for research purposes if it is a limited data set and is released pursuant to a data use agreement between researcher and covered entity). GINA or the Genetic Information Nondiscrimination Act prohibits discrimination in health coverage and employment based on genetic information. Id § 300gg-53. GINA prohibits employers, health insurers or group insurance plans from requesting that an individual have a genetic test, but it has a "research exception" to allow such a request if it is part of research provided the Federal government is notified, the genetic information is not used for non-research purposes (i. 
Id
Genetic Information Nondiscrimination
B. The IOM Report Addresses Consent in Information Based Research
The interaction between an individual's interests in control and privacy, and the public's more general interest in maximizing the benefits of research is the subject of a recent Institute of Medicine (IOM) report, chaired by Lawrence Gostin, Sharyl Nass, and Laura Levit. 88 The report concluded that HIPAA inadequately 183. See McGuire & Gibbs, supra note 180, at 370-71 (explaining how protective measures are needed to prevent the compromise of public trust due to rapidly proliferating DNA sequencing methods that would render previously "de-identified" information identifiable).
184 It advocates for a clear difference between interventional clinical research and information based research using medical records or stored tissue. 190 The IOM Committee report reasoned that consent requirements are less essential for information based research because consent requirements are "primarily considered a protection against physical harm," and it noted that, historically, "a great deal of informationbased health research was conducted using personally identifiable health records without the informed consent of the persons whose records were used."' 9 1 The report proposed that, instead of relying on consent, which, it argues, is poorly suited to protect privacy, the better approach is to directly strengthen and clarify privacy protections and improve security safeguards, including penalizing violators. According to the IOM report, the need to obtain informed consent hinders the ability to put together a large data network.1 96 Informed consent is less important in the context of information based research because current approaches overvalue the ability of informed consent to protect individuals' interests.1 97 Instead, we should strengthen effective privacy and security protections. Informed consent for information based research helps "ensure that individuals are able to exercise control over their personal information that is held by third parties, and to give individuals the right to determine whether their personal information can be used in a particular research project." 98 According to the report, participants should be allowed to consent for future information based research so long as an IRB to lessen informed consent requirements for human subject research include underestimating the risk to individuals, overvaluing research interests, and inadequate justification to eliminate informed consent for information based research approves, and the new study "is not incompatible with the original consent." 99 The creation of the new category of information-based research allows the JOM report to justify its divergence from the Nuremberg Code's specific and fundamental requirement that informed consent is essential in all research. 2 00 Information based research subjects' interests center on privacy, confidentiality, and control of their tissue. 201 In contrast, interventional research directly affects the subject's body and often impacts treatment choices; autonomy is more directly impacted. 202 Privacy and autonomy have similarities, but information based and interventional research impacts subjects differently, and informed consent is a better fit to protect the latter.
203
Although Ram and Gostin's IOM Committee both describe a tension between confidentiality/privacy and control/consent in the setting of informational research, 204 they fundamentally differ in how to resolve the conflict. Ram proposes greater control for the tissue providers by granting them informational property rights in their tissue and pursuing a copyright and copyleft approach. 205 The IOM report, conversely, seeks to downplay the importance of individual consent but strengthen security protections to guard against misuse of private information.
206
In summary, the IOMreport viewed current HIPAA and other applicable regulations as lacking the clarity and uniformity needed to effectively promote human research, especially information-based research, while meaningfully protecting privacy. 207 It emphasized that both privacy and health research are societal goods or public values, 20 8 and it carved out information-based research (including tissue research) as a category of research that invokes the advantages of scale and requires a protection scheme focused on privacy rather than the physical 199. Id.
See id at 124 (outlining the Nuremberg Code).
Informed consent requires that a research subject is informed of key facts about the research and any risks or benefits it poses. Id. at 126. The IOM's recommendation that research subjects provide "future consent" for research diverges from the Nuremberg Code because subjects will not be informed of what the future research involves. Id. at 33. 201. Id. at 33. 202. Id. The report also finds that "all interventional research" should be subject to "strong security measures," which would include research that directly impacts treatment. bodily integrity invoked by interventional research. 209 The researchers argued that these improvements are needed because the current uncertain and non-uniform privacy rules and overly stringent informed consent requirements hinder research and do not fully recognize the public health benefits of informational research.
210
C. Biobanks and the Problem of a Tissue Anticommons
The IOM report described a tissue anticommons without using that specific term. 211 Tissue donors and IRBs have the potential ability to exclude researchers from using tissue that sits in tissue repositories. 212 This is not only because of uncertain and inconsistent regulations and interpretations of privacy and informed consent rules, but also because federal law gives tissue donors the right to withdraw tissue samples after consent. 213 The result leaves no one with an exclusive privilege to use a scarce resource, because multiple persons have a right to exclude. Although the term "anticommons" is more commonly used to criticize the current state of biotech patents, it appropriately describes biobanks because continued uncertainty about what legal rights govern human tissue in a biobank may limit downstream use. 214 The uncertainty of future consent, of when, whether, and what type of informed consent will be required, along with the variability of de-identified tissue, all combine to hinder tissue research without giving tissue contributors added protections or information. 
209.
See id at 264-66 (advising Congress and agencies to develop a new approach to informationbased research that focuses on best practices in privacy, including program certification mechanisms, and imposing real consequences for mishandling personally identifiable health information).
210. Id. at 16, 35. 211. See id. at 214-27 (finding that compliance with the Privacy Rule impeded researchers during an information-based research study because it deterred recruitment and fostered unwillingness to grant authorization waivers). "Anticommons" refers to the underuse of a resource because multiple owners prevent others from having a privilege to use it. Heller & Eisenberg, supra note 97, at 698.
212. INST. OF MED., supra note 188, at 223 (noting the difficulty at times for researchers to obtain a waiver of authorization). 215. Kapp, supra note 127, at 336-37 (noting the difficulty of providing generic consent for future research projects).
See id at 48 (noting HHS
Indeed, Moore and progeny were concerned about creating a tissue anticommons, although they too did not use the term. 216 The Moore majority considered it an "important policy consideration" that they not create an environment where researchers ("innocent parties") were "threaten[ed] with disabling civil liability" that would result from having tissue with "uncertainty about clear title." 217 Moore noted that uncertainty about how courts will resolve legal rights in tissue might derail the "infant biotechnology industry" for academic researchers, and that the detrimental impact of uncertainty may extend to product development as well as research. 
D. The Case for Public Ownership of Tissue Based Information
Using an approach similar to the public health centered IOM report, Marc Rodwin has argued for the public ownership of anonymized or de-identified patient data. 233 He begins by reminding us that patient information, commonly deidentified or anonymized, has poorly defined property interests, but is routinely bought and sold. 234 De-identifying patient data results in privatization, even if it is not clearly acknowledged as property by current law. This is a mistake because it "precludes forming comprehensive databases required for many of its most important public health and safety uses."
235 For Rodwin, the better way is for patient data to be publicly owned. 236 He proposes mandatory federal reporting of Rodwin sets forth a two-pronged argument. First, the typical reasons favoring private over public ownership do not apply to patient data, and there is a tradition of state and federal reporting requirements for patient information. 239 Second, treating patient data as public property does not diminish privacy protections.
240
Risks are present whether private or public, and greater security measures are needed in either approach. 24 1 Current privacy protections for patient information are not based in patients having property rights in their health information, and the inability of patients to control resale of their information leaves them with an impotent either/or choice. 242 Public ownership of data may increase privacy protections because it has the added advantage of increased public oversight to ensure privacy guidelines are followed.243 Rodwin emphasizes the "well developed literature" that supports placing scientific information in the public domain.
244 Current norms, federal policies, the phenomenon of large networks, public health concerns, as well as the non-rival attributes of information, support the use of public property approaches in science and patient data. 245 Drawing on the work of Carol Rose and others, Rodwin argues that patient data is a public commons (with privacy safeguards) because aggregate patient data is like Rose's public roads, which are "most valuable when used by indefinite and unlimited numbers of persons-by the public at large." 253. See Rodwin, supra 233, at 595 (discussing legislation that will offer physicians and medical facilities financial incentives to adopt electronic medical records and ultimately encourage the sharing of patient data).
254. Id. at 587, 601; Ram, supra note 144, at 137-38. 258. See Heaney et al., supra note 257, at 55-56 (noting the public relations disaster Myriad faced in the wake of its scandal that was detrimental to the public's trust). Trust is also an important factor in patient data, granting individual donors' property rights introduces the risk of anticommons and does not offer the typical advantages true for other types of private property.
See
259
The most apparent difference between patient and tissue information is that patient information and tissue-derived information are non-rival, but the tissue itself is rival. 260 Tissue can be exhausted. Admittedly there are millions of tissue samples, but tissues from people with less common diseases remain scarce. 261 If a researcher uses all this tissue for a poorly designed project, there may be a social cost. In addition to the potential personal costs of a damaged reputation, there will be significant costs in replacing the scarce tissue so that others can use it. Tissue information, in contrast, is non-rival. 262 Once produced, it can be used by many people with no added cost.
26 3 There is a continuum between classic private property, such as a chair, and a perfect or inherent public good like Rose's public park. On one end of the spectrum is a rival and wholly excludable good, and on the other is a non-rival and non-excludable good. Tissue information is non-rival and partially non-excludable. 264 Tissue is partially rival (typically there is enough for more than one researcher), but exhaustible, and it is excludable. However, despite clear differences between tissue and tissue information, the two remain inexorably interrelated and each gains value as more information is added. 261. See Andrews, supra note 97, at 3 (discussing the extraordinary range of human tissue sources available to researchers); see also Cambron-Thomsen, supra note 260, at 867 (2004) (noting that in order to deal with the limited supply of certain tissues gathering multiple samples from one individual may be necessary to reach an appropriate sample size for a given study). 
IV. BIOBANKS AS A LIBERAL SEMICOMMONS
A. How a Biobank Best Fits the Description of a Liberal Semicommons
Biobanks contain human biospecimens and associated annotative information. 266 They are comprised of tissue and tissue information. 267 The interaction between tissue, information, and large numbers of both brings value.
268
These attributes make biobanks a semicommons, defined by Henry Smith as "exist[ing] where property rights are not only a mix of common and private rights, but both are significant and can interact." 269 Tissue is rival and amendable to being treated as private property, typically, as in Catalona and Greenberg, owned by the entity administering the tissue repository. 270 Tissue information, in contrast, is nonrival and often shared within a group that can be described as a commons, such as a university or research co-operative. 271 Describing biobanks as a semicommons recognizes the interaction between the tissue and the information derived from the tissue. By accurately describing biobanks as a semicommons, we can improve our understanding of how to best govern them. 271. See Meslin & Garba, supra note 264, at 459 (describing genetic information as non-rival). 272. Recognition of the dual nature biobanks is suggested by Yochai Benkler's description of a continuum between wholly excludable goods and public goods. See generally Benkler, supra note 260. He wrote: "Every good can be defined on a spectrum between a perfect economic good-which is rival and excludable, and a perfect public good-which is nonrival and nonexcludable. Information is generally understood to be perfectly nonrival and partially nonexcludable. Heller emphasize that we need not choose between the liberty offered by private property approaches and the strict cooperation mandated by a commons. 275 The "liberal commons" is a "participatory commons regime that also allows members the freedom to come and go." 276 Their notion of a liberal commons recognizes the ability of members to enter and withdraw from the commons without jeopardizing the continued successful operation of the commons. 277 Under the model of a liberal commons, patients/subjects may withdraw consent for use of their tissue at any time, which protects subjects' interests, promotes trust, and respects ethical norms. 278 One can, therefore, describe biobanks as having attributes of Henry
Smith's semicommons with aspects of Dagan and Heller's liberal commons. 279 No other description accurately accounts for the interaction between tissue and the information derived from the tissue.
B. Governing Biobanks as a Liberal Semicommons
We could treat all excised tissue not as private property but as common property. Under this model, a large pool of researchers would have a right to use excised tissue. This may address the concern that privatization leads to commodification, but it does not change the potential for profit by institutions while individuals who provided the tissue receive no financial benefit, and it does not recognize any tissue provider interests. 280 Some research would improve because of greater access to larger numbers of samples, but excised tissue is a limited natural resource, and researchers would use it up quickly for both well and poorly designed studies because there would be little cost, and significant potential commons). Relying on previous work by Ostrom, Gardner, and Walker, Acheson classified Maine's lobster fishery, which is a renewable resource but subject to over-fishing, as a common pool resource. Id. at 11. The fisheries are controlled for the benefit of the fishery, as well as the general public, which continues to be able to eat lobster. understand that those using a common natural resource can govern its use, as long as the commons meets certain design requirements. 2 8 7 For Ostrom, the wellfunctioning commons has a strong limit on alienability (rights to the commons cannot be transferred outside of the commons) along with a system of sanctions, Hardin, a professor of biology, argued that the incentives of a commons are such that each individual will continue to over-use the commons to the determent of others. Id. Things held in common, like water and air should be, therefore, regulated to prevent abuse. Id. at 1245 (describing how water and air show the tragedy of the commons through pollution and that coercive laws or taxing devices can be used to regulate this type of commons). So, too, Hardin argues, the "freedom to breed" should be limited by educating people about the dangers of the commons. 289 Together, this prior work gives guidance on how to govem natural resources like excised tissue and information derived from the tissue in order to create a well functioning commons.
290
A biobank is more than only tissue. It is also information derived from tissue.
29 1 As mentioned, biobanks inexorably combine non-rival information with rival, potentially excludable tissue, and both ideally gain greater value and usefulness over time. 292 Tissue information can be shared with others for much less than it costs to initially obtain the information, and there is public benefit to making the tissue information widely available. 293 The potential problem is that there may be little concrete economic benefits to create the tissue information if there is no ability to exclude another's use. All one has to do is wait until another researcher does the work and then get a free ride.
Avoiding this free rider problem and providing incentives is one justification for creating intellectual property rights so that the producers of the product can exclude others, make money through licensing, and recoup costs. 294 There are, however, disadvantages with this approach. Enforcing exclusion is expensive,
288.
Id. at 90 tbl.3.1. Ostrom did not require shared normative beliefs for members for the common's survival. Id. In contrast, Michael Taylor says stable membership requires normative beliefs beyond their collective action. See Dagan & Heller, supra note 27, at 564 (comparing the view of both Ostrom and Taylor and describing that for Taylor "a community is a more or less stable set of members with some shared beliefs, including normative beliefs and preferences beyond those constituting their collective action problem, who expect to continue interacting with one another . . . and whose relations are direct . . . and multiplex").
which will raise the price of the information, and lead to underuse and suboptimal social benefit. 295 Also, in the context of biobanking, datasets are presumed not to be subject to copyright, although publications analyzing and drawing conclusions from the data are subject to copyright. 296 The challenge is typically not collecting data, but making meaningful use of the data. Moreover, the free rider problem may be minimal in the setting of tissue information. Researchers are driven by personal ambition, peer recognition, promotion, generosity, reciprocity, and other social motivations. Grants and prizes implicitly recognize the public good of tissue information and fund much tissue research. 297 Being "first to market" offers marketing benefits to commercial interests. 298 And on a larger scale, spillovers or externalities enhance social welfare. 299 Easily obtained, cheap information will lead to more information, not less.
300
A semicommons has its own set of potentially destructive incentives. A biobank semicommons, with its combination of tissue and tissue information, potentially combines the worst of both private property and commons. In a commons lacking governance, the incentives are to overuse and under-invest, with members of the commons enjoying short-term benefit without investment. a semicommons, those with access to the commons cannot easily be excluded from its privately owned attributes."); see also EISEMAN ET AL., supra note 310, at 117 (noting that the University of Pittsburgh Health Sciences Tissue Bank provides researchers reserves some tissue for pilot projects, but also maintains a fee structure for additional specimens).
313. Smith, supra note 312, at 294. 314. See EISEMAN ET AL., supra note 310, at 128 (noting that, in addition to IRB oversight, all of the repositories in the case study protect the confidentiality of patients through guidelines, policies, and procedures); see also INST. OF MED., supra note 188, at 98-99 (noting that the Institute of Medicine recommends that all institutions involved in the collection, use, and disclosure of patient-identifying information take measures to safeguard the security of health data, such as appointing a security officer on IRBs and Privacy Boards, using encryption and encoding techniques, and implementing a breach notification requirement). 325 The project recognized the advantages of a national network of researchers pooling efforts, leveraging scale and infrastructure, and making data freely and openly available. 326 It created a data portal that provides an open platform for researchers to search, download, and analyze data generated by TCGA. 327 The project includes a "Biospecimen Core Resource," which operates as a centralized biobank. 328 It also invested significant resources for software development (freely available), because it recognized that new technologies produce immense amounts of data, and meaningful analysis is critically important. 329 However, the lessons show that sernicommons governance should include consent by tissue contributors to allow that their excised tissue can be used for research, and that they have the ability to withdraw their tissue and their tissue information. 330 The consent would include an acknowledgment that the tissue is not wholly anonymous and that the tissue, and tissue information could be used for unspecified future research, subject to withdrawal. The consent would also include notification that tissue information already utilized in research analysis could not be withdrawn, although it could likely be retrospectively anonymized. Tissue contributors would be members of the tissue semicommons and have access to secured de-identified data. 33 1 With this information they could participate in debates about tissue use, and perhaps track how researchers have used their tissue. Such an approach is consistent with the direction proposed by the current working group that is looking at how to reform the Common Rule, which governs most (but not all) research today, and it is also consistent with current approaches to clinical information, which give patients the right to access their medical record.
See OFFICE OF BIOREPOSITORIES & BIOSPECIMEN RESEARCH, DEP'T OF HEALTH
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C. Questions Raised
The liberal semicommons approach raises many questions. For example, how might this new approach impact intellectual property derived from work on biobanked tissue? Gene patents remain controversial, as illustrated by the discussions surrounding the recent Myriad case about the patentability of the BRCA gene. 333 Treating tissue and tissue information as a semicommons is
330.
See EISEMAN ET AL., supra note 310, at 132, 144 (noting that concerning tissue repositories, informed consent, a process that educates and provides information to the participant about the details of the research, is crucial for protecting the interests and rights of research participants, and it is best practice to allow the withdrawal of consent).
331. Cf BLUEPRINT, supra note 307, at 44 (proposing that de-identified tissue information could be made available through a secure web-based platform). Some people may be concerned that tissue contributors may misinterpret data, but most of the data produced would not provide clear answers and recent controversy about direct to consumer DNA information suggests that such fears may be Much of the rich body of scholarly work about how to protect informational privacy in the internet age applies to biobanks as semicommons. Some information privacy scholars object to using property interests to safeguard private information because property gives the right to freely buy and sell (it is freely alienable), leading to market failures and inadequate privacy protections. 44 Others, like Professor Paul Schwartz, advocate the use of property interests as the best way to protect private information, although they acknowledge the necessity of strict limitations, including limiting alienability and recognizing that privacy is a public good. 345 The property framework offered by a biobank semicommons would strengthen tort law's ability to set a "baseline" for privacy and confidentiality protections. 346 A liberal semicommons approach to biobanked tissue is a tempered property approach that may capitalize on some of the advantages of using property to protect privacy and allow individuals greater control over "their" information, but the details of the additional needed privacy protections need further work. 343. See Sorrell, 131 S. Ct. at 2659-60 (observing that to maximize profits, pharmaceutical salespersons promote high-profit drugs to targeted physicians they foresee being interested in prescribing them).
344. See Samuelson, supra note 242, at 1138 ("Free alienability works very well in the market for automobiles and land, but it is far from clear that it will work well for information privacy."); see also Schwartz, supra note 242, at 2076 (discussing how existing markets for privacy lead to undesired results and market failures).
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